Positive Data, Lease Agreements, and Product Launches Strengthen Portfolio - Research Report on Celldex, Teva, Health Management, Perrigo, and Alnylam

NEW YORK, July 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Celldex Therapeutics, Inc. (NASDAQ: CLDX), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Health Management Associates Inc. (NYSE: HMA), Perrigo Company (NYSE: PRGO), and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Celldex Therapeutics, Inc. Research Report

On July 1, 2013, Celldex Therapeutics Inc. (Celldex) reported that the first patient has been dosed in its pilot study of CDX-1135 (a soluble form of human complement receptor type 1) in dense deposit disease (DDD). According to the Company, DDD is an ultra-rare, progressive kidney disease that results in kidney failure in the majority of affected individuals, and is caused by dysregulation of the C3 Convertase, a major early component of the alternative pathway of complement. J.H. Smith, M.D., said, "There are currently no treatments and nearly half of all patients progress to end-stage renal disease within 10 years of presentation, often spending the rest of their lives on dialysis. In a mouse model of dense deposit disease, CDX-1135 has been shown to control the abnormal complement activity and to reduce deposits in the kidneys. We are optimistic that if we can control complement activation earlier in the disease course and at a critical step in the complement pathway, CDX-1135 may be able to restore kidney function and provide long term disease control-a long-awaited outcome for patients, their families and physicians." The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/bd46_CLDX]

--

Teva Pharmaceutical Industries Ltd. Research Report

On July 1, 2013, Teva Pharmaceutical Industries Ltd. (Teva) announced that data from the Glatiramer Acetate Low-frequency Administration (GALA) study, which was published in the Annals of Neurology, show that a 40mg/ 1mL dose of COPAXONE (glatiramer acetate injection) administered subcutaneously three times per week significantly reduced relapse rates at 12 months and demonstrated favorable safety and tolerability profile in patients with relapsing-remitting multiple sclerosis (RRMS). Omar Khan, M.D., Professor of Neurology and Chair of the Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, said, "We are pleased with the positive data of the GALA study which may lead to meaningful benefits for RRMS patients. COPAXONE 40mg/ 1 mL given three times a week demonstrated a favorable safety and tolerability profile, with the overall frequency of adverse events comparable to those seen in the placebo group." At present, the approved dose of COPAXONE is 20 mg/ 1mL, which is a once a day subcutaneous injection. The Full Research Report on Teva Pharmaceutical Industries Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/e4ac_TEVA]

--

Health Management Associates Inc. Research Report

On June 26, 2013, Health Management Associates Inc. (Health Management) announced that the Southeast Volusia Hospital District Board of Commissioners chose it to start exclusive negotiations towards a lease agreement for the 112-bed Bert Fish Medical Center in New Smyrna Beach, Florida. Alan Levine, Senior Vice President and Florida Group President for Health Management, said, "Our mission at Health Management is to enable America's best local health care, and we pledge to serve that mission at Bert Fish Medical Center." According to Health Management, Bert Fish Medical Center will join its network in Florida, which currently includes 23 hospitals and a statewide clinical affiliation with the University of Florida's affiliated teaching hospital, Shands Hospital. The Full Research Report on Health Management Associates Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/96e5_HMA]

--

Perrigo Company Research Report

On July 2, 2013, Sergeant's Pet Care Products, Inc. (Sergeant's), a part of Perrigo Company (Perrigo), reported the availability of Vetscription PetSTOP! Behavior Correction Spray for Dogs and Cats at Wal-Mart stores nationwide. Sergeant's stated that PetSTOP! Behavior Correction Spray helps modify destructive or aggressive behavior by combining noise and a specifically developed pheromone mist. The pheromone in the PetSTOP! Spray mimics a natural pheromone that a mother dog or cat produces to calm and assure her young. Further, Sergeant's stated that unlike other noise-making products that produce a temporary effect, the spray's patent pending pheromone mist redirects the pet's attention and behavior. The Full Research Report on Perrigo Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/4961_PRGO]

--

Alnylam Pharmaceuticals, Inc. Research Report

On July 2, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders. Alnylam stated that the new pre-clinical data demonstrate that ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), can normalize thrombin generation and improve hemostasis in hemophilia mice and fully correct thrombin generation in a non-human primate (NHP) hemophilia "inhibitor" model. Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam, said, "We are very excited by these new data with ALN-AT3 which demonstrate normalization of thrombin generation and improvement of hemostasis in hemophilia models. Most importantly, we have demonstrated that ALN-AT3 can fully correct thrombin generation in a non-human primate hemophilia 'inhibitor' model, providing key proof of concept for our program." The Company expects to file an investigational new drug application for ALN-AT3 in mid-2013 and to initiate its Phase I study in late 2013. The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/5328_ALNY]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


SOURCE Wall Street Reports

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.